Yeah the trend since the Pit Hopkins result (Late May) has been interesting to say the least.
The news for both companies have largely been about Daybue (good and bad). We seem to be punished higher (proportionally) given the lack of other news. Acadia on the other hand hasn't had a good year either but they have recovered a lot and they also failed a Nuplazid Phase 3 trial to expand (label extension) into controlling certain symptoms of schizophrenia. That's what caused that additional large decline in march.
Acadia has done a bit better with Nuplazid than expected, but Neuren also announced the Angelman phase 2 results in August.
NEU Price at posting:
$13.19 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)